Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery
- 4 November 1994
- Vol. 149 (1) , 13-19
- https://doi.org/10.1016/0378-1119(94)90406-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.Journal of Clinical Investigation, 1994
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Direct in vivo gene introduction into rat kidneyBiochemical and Biophysical Research Communications, 1992
- A transcriptional trystNature, 1991
- Restenosis after coronary angioplasty: An overviewJournal of the American College of Cardiology, 1991
- Re-Stenosis after Successful Coronary AngioplastyNew England Journal of Medicine, 1988
- The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosidesExperimental Cell Research, 1987
- Efficient introduction of contents of liposomes into cells using HVJ (Sendai virus)Experimental Cell Research, 1985
- Modification of cell membranes with viral envelopes during fusion of cells with HVJ (Sendai virus): I. Interaction between cell membranes and virus in the early stageExperimental Cell Research, 1975
- Injection of foreign substances into single cells by cell fusionNature, 1974